KKR (as anticipated) recently agreed to buy Ivirma in a deal valuing the global fertility treatment giant at €3 billion ($3.2 billion) or more, three sources tell Sarah.
Why it matters: As startups left and right emerge to tackle fertility inequality challenges and drive up utilization, KKR has swiftly made a huge splash in assisted reproduction technology.
